Condition: Type 2 Diabetes · Sponsor: The George Institute
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
This description comes directly from the study's public registry record.
Emma Zhang · +61 2 8052 4337 · ezhang1@georgeinstitute.org.au
Sarah Stanton · sstanton@georgeinstitute.org.au
Always discuss trial participation with your own doctor first.
| The George Institute for Global Health | Sydney, New South Wales, Australia | Recruiting |
| The George Institute for Global Health | Brisbane, Queensland, Australia | Recruiting |
| Monash University | Melbourne, Victoria, Australia | Recruiting |
| National Hospital - Galle | Galle, Southern Province, Sri Lanka | Not Yet Recruiting |
| National Hospital of Sri Lanka 1 | Colombo, Sri Lanka | Recruiting |
| National Hospital of Sri Lanka 2 | Colombo, Sri Lanka | Not Yet Recruiting |
| Jaffna Teaching Hospital | Jaffna, Sri Lanka | Recruiting |
| Kandy National Hospital | Kandy, Sri Lanka | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05345327